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Neuregulin 1 (Nrg1) is a susceptibility gene of schizo-
phrenia, a disabling mental illness that affects 1% of
the general population. Here, we show that ctoNrg1
mice, which mimic high levels of NRG1 observed in
forebrain regions of schizophrenic patients, exhibit
behavioral deficits and hypofunction of glutama-
tergic and GABAergic pathways. Intriguingly, these
deficits were diminished when NRG1 expression re-
turned to normal in adult mice, suggesting that dam-
age which occurred during development is recover-
able. Conversely, increase of NRG1 in adulthood
was sufficient to cause glutamatergic impairment
and behavioral deficits. We found that the glutama-
tergic impairment by NRG1 overexpression required
LIM domain kinase 1 (LIMK1), which was activated in
mutant mice, identifying a pathological mechanism.
These observations demonstrate that synaptic
dysfunction and behavioral deficits in ctoNrg1 mice
require continuous NRG1 abnormality in adulthood,
suggesting that relevant schizophrenia may benefit
from therapeutic intervention to restore NRG1
signaling.
INTRODUCTION
Schizophrenia is a common and disabling mental illness that
affects 1% of the population worldwide and accounts for 3%
of the total economic burden of human disease (Murray and
Lopez, 1996). Schizophrenia is believed to be a neural develop-
mental disorder with strong genetic factors (Lewis and Levitt,
2002; Weinberger, 1987). Neuregulin 1 (NRG1) is a large family
of EGF-domain-containing trophic factors (Mei and Xiong,
2008). Its gene, Nrg1, has been identified as a schizophrenia
susceptibility gene in diverse populations (Shi et al., 2009; Ste-
fansson et al., 2009; Stefansson et al., 2003; Stefansson et al.,644 Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc.2002; Yang et al., 2003). Exactly how Nrg1 gene variations
lead to schizophrenia remains unclear.
Most of the single nucleotide polymorphisms (SNPs) in the
Nrg1 gene that are associated with schizophrenia are localized
in intronic, noncoding regions (Mei and Xiong, 2008), raising the
possibility that they may regulate the expression of the Nrg1
gene. Expression of isoform 1 alpha of NRG1 was lower in brains
of schizophrenic patients (Bertram et al., 2007; Parlapani et al.,
2010). Nrg1 hypomorphs are impaired in relevant behaviors
(Bjarnadottir et al., 2007; Chen et al., 2008; Gerlai et al., 2000;
O’Tuathaigh et al., 2007; Rimer et al., 2005; Stefansson et al.,
2002). Recently, elevated NRG1 levels or signaling have been
implicated in schizophrenia. The HapICE risk haplotype is asso-
ciated with increased expression of NRG1 in the brain (Weickert
et al., 2012).Moreover,mRNAandprotein of NRG1are increased
in the prefrontal cortex (PFC) and hippocampus of schizophrenia
patients (Chong et al., 2008; Hashimoto et al., 2004; Law et al.,
2006; Petryshen et al., 2005). The increase did not correlate
with antipsychotics treatment (Chong et al., 2008; Law et al.,
2006), suggesting an association with the disorder instead of
medication. Likewise, NRG1 signaling was increased in the fore-
brain of patients (Hahn et al., 2006). In agreement, transgenic
mice overexpressing NRG1 exhibit relevant behavioral deficits
(Deakin et al., 2009; Deakin et al., 2012; Kato et al., 2010).
Consistent with the neurodevelopmental hypothesis of schizo-
phrenia, NRG1 has been implicated in brain development
(Barros et al., 2009; Fazzari et al., 2010; Flames et al., 2004;
Makinodan et al., 2012; Mei and Xiong, 2008; Ting et al., 2011).
However, it remains unclear whether damage done by abnormal
NRG1 signaling during development is reversible. NRG1 is
known to regulate neurotransmission and synaptic plasticity
(Bjarnadottir et al., 2007; Chang and Fischbach, 2006; Chen
et al., 2010; Gu et al., 2005; Huang et al., 2000; Kwon et al.,
2005; Li et al., 2007; Pitcher et al., 2011; Wen et al., 2010; Woo
et al., 2007), raising another question whether relevant behav-
ioral deficits require continuous abnormal NRG1 signaling in
adulthood. To address these critical questions, we generated
ctoNrg1 mice which overexpress type I NRG1, mimicking high
levels of NRG1 in schizophrenic patients (Hashimoto et al.,
2004; Law et al., 2006; Petryshen et al., 2005). Expression of
Neuron
Reversal of Schizophrenia-like Deficits in MiceNrg1 transgene in ctoNrg1 mice was restricted to forebrain
regions including PFC and hippocampus, areas increasingly
implicated in schizophrenia (Harrison, 2004; Weinberger et al.,
1986). The ctoNrg1 mice showed relevant behavioral deficits
and were impaired in glutamatergic and GABAergic transmis-
sion. Unexpectedly, both synaptic dysfunction and behavioral
deficits disappeared when expression of the Nrg1 transgene
was switched off in adult mice. Moreover, turning on the trans-
gene expression in adulthood alone was sufficient to cause
impaired glutamatergic transmission and behavioral deficits.
We studied mechanisms underlying synaptic dysfunction in
ctoNrg1 mice. Results indicate that glutamatergic hypofunction
caused by NRG1 overexpression requires LIMK1, but not
ErbB4, identifying a pathogenic mechanism. Together, these
observations demonstrate that synaptic dysfunction and behav-
ioral deficits require continuous NRG1 abnormality in adulthood.
Our results suggest that relevant schizophrenia may benefit from
therapeutic intervention to restore NRG1 signaling.
RESULTS
Spatial and Temporal Control of Type I NRG1Expression
in ctoNrg1 Mice
Tomimic high levels of NRG1 type I in schizophrenic patients, we
generated transgenic mice, TRE-Nrg1, which carry the type I
NRG1b cDNA under the control of the tetracycline-responsive
promoter element (TRE) tetO (Figure 1A). An HA tag was inserted
between the Ig and EGF domains, which has no effect on NRG1
processing and function (Wang et al., 2001). TRE-Nrg1mice did
not express Nrg1 transgene in the absence of tetracycline
transactivator (tTA) (Figures 1B and 1C). Since the majority of
NRG1 in the brain is produced in excitatory neurons (Brinkmann
et al., 2008; Liu et al., 2011) and NRG1 increase was observed in
forebrain areas of schizophrenic patients (Chong et al., 2008;
Hashimoto et al., 2004; Law et al., 2006), TRE-Nrg1 mice were
crossed with CamK2a-tTA mice that express tTA in excitatory
neurons (Mayford et al., 1996). Resulting bitransgenic
CamK2a-tTA;TRE-Nrg1 mice (ctoNrg1 for CamK2a promoter-
driven tet-off Nrg1) produced HA-NRG1 in excitatory neurons
in the absence of doxycycline (Dox) (Figures 1B and 1C).
Compared with TRE-Nrg1 or control mice, NRG1 was increased
by 50%–100% in forebrain of ctoNrg1mice (Figures 1C and 1D),
similar to levels in forebrain of schizophrenic patients. The
increase was due to expression of the transgene, which was
detectable by anti-HA antibody (Figures 1C, 1E, and 1F). More-
over, the increase was forebrain specific and not detectable in
the midbrain and cerebellum (Figures 1C and 1D), in agreement
with the expression of CamK2a-tTA (Mayford et al., 1996). The
expression of transgene occurred as early as postnatal day 0
and remained into adulthood (Figures 1G and 1H). Finally, the
overexpression of NRG1 could be switched off by Dox (Figures
1C–1F). Together, the results indicate that ctoNrg1mice express
higher levels of NRG1 in the forebrain during development, and
the expression could be turned off efficiently by Dox.
Behavioral Deficits in ctoNrg1 Mice
Compared to controls, ctoNrg1 mice displayed normal motor
skill learning on rotarod test (see Figure S1A available online)and did not exhibit an anxiety-like phenotype in elevated plus
maze ( Figures S1B–S1E). However, they were hyperactive in
open-field test (Figure 2B), a phenotype thought to correspond
to psychomotor agitation in schizophrenic patients (Snyder,
1973). Prepulse inhibition (PPI) is a common test of sensory-
motor gating that is often decreased in schizophrenic patients.
ctoNrg1 mice had a slightly elevated response to 70 dB back-
ground noise (Figure 2C), suggesting no deficit in hearing, and
produced similar startle amplitude (Figure S1F). However, PPI
was impaired in ctoNrg1mice, compared to controls (Figure 2D).
Social withdrawal is a negative symptom of schizophrenia
(Corcoran et al., 1995). ctoNrg1 and control mice showed no dif-
ference in the time spent around a cylinder without a stimulus
mouse inside (Figure 2E). However, the time spent around the
social cylinder with a stimulus mouse inside was significantly
reduced in ctoNrg1 mice, compared to controls (Figure 2E).
Moreover, the social interaction time of ctoNrg1 mice with the
stimulus mouse was reduced, compared to controls (Figure 2F).
These results suggest impaired social activity in ctoNrg1 mice.
To determine the effect of NRG1 overexpression on cognitive
function, we tested spatial working memory and reference
memory in 8-arm radial maze (ARM) and Morris water maze
(MWM), respectively (Hodges, 1996; Morris, 1984). To exclude
potential influence of hyperactivity in the 8 ARM test, we moni-
tored correct entries during the first eight entries. They were
reduced in ctoNrg1mice compared to controls (Figure 2G), indi-
cating deficient spatial working memory. In MWMs, ctoNrg1
mice had no problem in visualizing the platform (Figure S1G)
and were able to learn to locate the submerged platforms. How-
ever, the latency to find the platformwas increased, compared to
controls (Figure 2H), indicating compromised ability to learn. In
the probe trial, the number of times that ctoNrg1 mice swam
across the platform location decreased, compared to controls
(Figure 2I). These results indicate that ctoNrg1mice are impaired
in spatial reference memory. The above results demonstrate that
NRG1 overexpression in the forebrain causes behavioral deficits
in locomotor activity, sensory-motor gating, social interaction,
and cognitive function, in agreement with recent studies (Deakin
et al., 2009, 2012; Kato et al., 2010). Finally, administration of clo-
zapine, an antipsychotic medication for schizophrenic patients
(Krakowski et al., 2006), ameliorated behavioral deficits of
ctoNrg1 mice in open field, PPI and social interaction tests
(Figure S2).
Hypofunction of Glutamatergic and GABAergic
Transmission in ctoNrg1 Mice
ctoNrg1 mice showed normal laminar structure and densities of
excitatory and parvalbumin (PV)-positive neurons in the somato-
sensory cortex and hippocampus (Figure S3). Intriguingly, there
was a downward shift of input-output (I/O) curves of fEPSPs
(field excitatory postsynaptic potentials) at Schaffer collateral
(SC) – CA1 synapses in ctoNrg1 hippocampus, compared to
controls (Figure 3B), suggesting hypofunction of glutamatergic
transmission. To determine if the impairment is caused by
reduced glutamate receptors or decreased glutamate release,
we measured miniature excitatory postsynaptic currents
(mEPSCs) in CA1 pyramidal neurons in the presence of TTX to
block action potentials. No difference was observed in mEPSCNeuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc. 645
Figure 1. Temporal Control of NRG1 Expression in Forebrains of ctoNrg1 Mice
(A) Transgene structure. Full-length NRG1 type I b1a was cloned in pMM400 between the promoter complex of TRE and CMV (cytomegalus virus minimal
promoter) and SV40 polyadenylation signal.
(B) Genotypes and NRG1 expression. Unless otherwise indicated, blank, red, and blue histograms/curves in the paper represent data from control, ctoNrg1, and
aDox-treated ctoNrg1 mice, respectively. aDox, Dox treatment in adulthood; dDox, Dox treatment during development (see Figure 7); o/e, overexpression.
(C) Expression of NRG1 transgene in PFC, hippocampus (HPF), and striatum (STR), but not midbrain (MB) and cerebellum (CB). ctoNrg1mice, 8 weeks of age,
were treated with Dox for 2 weeks. Homogenates of various brain regions of indicated mice were subjected to Western blot analysis with indicated antibodies.
(D) Quantification of NRG1 expression in different brain regions. Expression in ctoNrg1 samples were normalized by those from control littermates. n = 3 per
genotype; ***p < 0.001 for PFC, HPF, and STR, one-way ANOVA. Data were presented as mean ± SEM.
(E) HA staining in ctoNrg1 PFC. Sections were stained with anti-HA antibody and DAPI. Bar, 50 mm.
(F) HA staining in ctoNrg1 hippocampus. Sections were stained with anti-HA antibody. Bar, 100 mm.
(G andH) NRG1 expression of developing forebrains. Top, representative western blots; bottom, quantitative analysis. n = 3 per genotype at each time point. Data
were normalized by NRG1 levels of E18 control mice (in G) or of P7 control mice (in H). In (G), **Genotype F (1, 20) = 184, p < 0.01, two-way ANOVA. In (H),
**Genotype F (1, 16) = 33.03, p < 0.01, two-way ANOVA. Data were presented as mean ± SEM.
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Moreover, the ratio of AMPAR to NMDAR EPSCs (AMPA/
NMDA ratio) (Figure S4A) and protein levels of NMDAR, AMPAR,
and PSD95 were similar between the two genotypes (Fig-
ure S4B). These results suggest that NRG1 overexpression did
not alter glutamate receptor density or composition. However,
mEPSC frequencywas decreased in ctoNrg1 hippocampus (Fig-
ure 3C) and PFC (Figure S4C). Since reduction of mEPSC fre-
quency suggests impaired glutamate release or fewer functional
synapses, we measured fEPSPs evoked by two presynaptic
stimulations delivered at different intervals (i.e., paired pulses).
Paired-pulse facilitation (PPF) of initial slopes of fEPSPs was
increased in ctoNrg1 slices, compared to controls, suggesting646 Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc.lowered release probability (Figure 3D). Moreover, the rate of
synaptic fatigue during high-frequency stimulation was slower
in ctoNrg1 slices (Figure S4D). Together, these observations
suggest that the glutamatergic pathway is hypofunctional in
ctoNrg1 mice, probably due to impaired glutamate release.
To determine if NRG1 overexpression alters GABAergic
transmission, miniature inhibitory postsynaptic currents
(mIPSCs) were first recorded at a holding potential of +10 mV
in a Cs-methanesulfonate-based internal solution (Zhou et al.,
2009). mIPSC amplitudes were reduced in ctoNrg1 mice,
compared to controls (Figure S5A). To enhance the driving force
of Cl currents, we also recorded mIPSCs at a holding potential
of 70 mV with high concentration of CsCl in internal solution
Figure 2. Behavioral Deficits in ctoNrg1 Mice Were Attenuated after aDox Treatment
(A) Diagram of aDox treatment and behavioral test. Dox was added in the drinking water when mice were 8 weeks old and during behavioral tests, which started
2 weeks after treatment.
(B) Travel distance in open field was increased in ctoNrg1mice, compared to controls, but became similar between the genotypes after aDox treatment. n = 12
per group; *p < 0.05, #p > 0.05, one-way ANOVA. Blank, red, gray, and blue histograms/curves represent data from control, ctoNrg1, aDox-treated control and
aDox-treated ctoNrg1 mice, respectively.
(C) Elevated response to 70 dB background noise in ctoNrg1mice compared to controls. The elevation was ameliorated by aDox treatment. AU, arbitrary units.
n = 9 per group; *p < 0.05, #p > 0.05, one-way ANOVA.
(D) PPI was impaired in ctoNrg1mice, compared to controls, and the impairment was diminished after aDox treatment. n = 9 per group; *Genotype F (3, 84) = 10.2,
p < 0.05, two-way ANOVA.
(E) ctoNrg1 mice spent less time around social cylinder with stimulus mouse, compared to controls, and the interaction time was similar between the two ge-
notypes after aDox treatment. n = 12 per group; *Genotype F (3, 172) = 7.01, p < 0.05, two-way ANOVA.
(F) Social interaction time with stimulus mice without cylinder was reduced in ctoNrg1 mice, and the reduction was diminished after aDox treatment. n = 12 for
each group; *p < 0.05, #p > 0.05, one-way ANOVA.
(G) Decreased correct entries in ctoNrg1 mice, compared to controls, and the difference was diminished after aDox treatment. n = 12 per group; **Genotype F
(3, 424) = 16.14, p < 0.01, two-way ANOVA.
(H) Increased latency for ctoNrg1 mice to reach the hidden platform in MWM, compared to controls, and the two genotypes showed similar latency after aDox
treatment. n = 9 for control, n = 8 for ctoNrg1, n = 8 for both groups of control + aDox and ctoNrg1 + aDox; *Genotype F (3, 87) = 6.4, p < 0.05, two-way ANOVA.
(I) Reduced platform crossing by ctoNrg1 mice in MWM probe test, compared to controls, and the two genotypes showed similar platform crossing after aDox
treatment. n = 9 for control, n = 8 for ctoNrg1, n = 8 for both groups of control + aDox and ctoNrg1 + aDox; *p < 0.05, #p > 0.05, one-way ANOVA. Data were
presented as mean ± SEM.
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dition were similarly reduced in ctoNrg1 slices (Figure 3E).
These results suggest reduced GABAA receptor density in
ctoNrg1 mice. This notion was supported by biochemical data
that GABAA receptor a1 subunit (GABAAR a1) was decreased
in ctoNrg1 forebrain (Figure 3F). Notably, mIPSC frequency
was similar between ctoNrg1 and control mice by the twomethods (Figures S5A and 3E), suggesting no change in
spontaneous GABA release. The paired-pulse ratios (PPRs) of
evoked inhibitory postsynaptic currents (eIPSCs) in response
to two stimulations were comparable between two genotypes
(Figure S5B). These observations indicate that GABAergic
transmission is impaired in ctoNrg1 mice, mainly due to a post-
synaptic mechanism.Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc. 647
Figure 3. Glutamatergic and GABAergic Impairment in ctoNrg1 Mice Was Reduced after aDox Treatment
(A) Diagram of aDox treatment and behavioral test. Mice were fedwith Dox-containing drinkingwater at 8weeks old for 2 weeks before recording. Doxwas kept in
the slice perfusion solution.
(B) Depressed I/O curves in ctoNrg1 mice compared to controls. I/O curves were similar between the genotypes after aDox treatment. Left, representative
traces of fEPSPs at SC-CA1 synapses at different stimulus intensities; right, I/O curves of four groups. n = 10 slices from 6 control mice, n = 10 slices from
6 ctoNrg1mice, n = 9 slices from 4 aDox-treated control mice, n = 8 slices from 4 aDox-treated ctoNrg1mice; **Genotype F (3, 429) = 19.87, p < 0.01, two-way
ANOVA.
(C) Reduced mEPSC frequency in ctoNrg1 CA1 pyramidal neurons compared to controls. mEPSC frequency was similar between the two genotypes after aDox
treatment. Left, representative mEPSC traces; right, quantitative data. n = 10 cells from 4 mice per group; **p < 0.01, #p > 0.05, one-way ANOVA.
(D) Elevated PPF at ctoNrg1 SC-CA1 synapses compared to controls. PPF was similar between the two genotypes after aDox treatment. Top, representative
traces; bottom, quantitative data. n = 10 slices from 6 control mice, n = 10 slices from 6 ctoNrg1mice, n = 8 slices from 4 aDox-treated control mice, n = 8 slices
from 4 aDox-treated ctoNrg1 mice; ***Genotype F (3, 201) = 29.76, p < 0.001, two-way ANOVA.
(E) Attenuated mIPSC amplitudes in ctoNrg1 CA1 pyramidal neurons compared to controls. mIPSC amplitudes were similar between the two genotypes after
aDox treatment. Left, representative mIPSC traces; right, quantitative data. n = 11 cells from 5 control mice, n = 10 cells from 4 ctoNrg1mice, n = 11 cells from
5 aDox-treated control mice, n = 10 cells from 4 aDox-treated ctoNrg1 mice; *p < 0.05, #p > 0.05, one-way ANOVA.
(F) ReducedGABAA receptor a1 subunit (GABAARa1) in ctoNrg1 forebrain. The reduction was diminished after aDox treatment. Top, representative blots; bottom,
quantitative data. Data from other three groups were normalized by control. n = 3 per group; *p < 0.05, #p > 0.05, one-way ANOVA. Data were presented as
mean ± SEM.
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Continuous NRG1 Overexpression
To determine whether behavioral deficits in ctoNrg1 mice
require continuous NRG1 overexpression, mice were subjected
to aDox treatment (adult Dox treatment) (Figure 2A). To elimi-
nate possible compounding effects of Dox, control mice were
subjected to identical aDox treatment. aDox treatment effec-
tively shut off NRG1 overexpression (Figures 1C and 1D).
Notably, aDox-treated ctoNrg1 and control mice traveled
similar distance in the open field (Figure 2B), suggesting normal648 Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc.locomotive activity of aDox-treated ctoNrg1 mice. Moreover,
no difference was observed in PPI between aDox-treated con-
trol and ctoNrg1 mice (Figure 2D). In addition, social interaction
deficits in ctoNrg1 mice were ameliorated by aDox treatment
(Figures 2E and 2F). Finally, aDox-treated ctoNrg1 mice
performed normally in 8-ARM and MWM test (Figures 2G–2I),
indicating normal cognitive function. These results demonstrate
that behavioral deficits in ctoNrg1 mice require continuous
NRG1 overexpression in adulthood and are reversible by
aDox treatment.
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be diminished when NRG1 expression returns to normal. To
test this, aDox-treated mice were subjected to electrophysio-
logical studies (Figure 3A). I/O curves at SC-CA1 synapses
were similar between aDox-treated control and ctoNrg1 mice
(Figure 3B), indicative of normal AMPAR-mediated glutamater-
gic transmission. mEPSC frequencies of aDox-treated ctoNrg1
and controls were also similar (Figure 3C). PPF, which was
increased in ctoNrg1 mice, showed no difference between the
two genotypes after aDox treatment (Figure 3D). In addition,
mIPSC amplitude (Figure 3E) and GABAAR a1 level (Figure 3F)
were also similar between aDox-treated control and ctoNrg1
mice. These observations demonstrate the dependence of
synaptic dysfunction in ctoNrg1 mice on continuous NRG1
overexpression and underscore the importance of synaptic
dysfunction in behavioral deficits.
ErbB4 Is Dispensable for Impaired Glutamate Release
in ctoNrg1 Mice
ErbB4, a critical receptor for NRG1, has been implicated in
regulation of GABAergic transmission and synaptic plasticity
(Chen et al., 2010; Pitcher et al., 2008; Wen et al., 2010; Woo
et al., 2007). To investigate if ErbB4 is involved in synaptic
dysfunction in ctoNrg1 mice, we determined whether ErbB4
expression was altered. The level of ErbB4, enriched in cortical
P2 fractions (Huang et al., 2000), was similar between ctoNrg1
and control mice, regardless of Dox treatment (Figure S6A).
ErbB4 activation in forebrain, revealed by anti-phospho-ErbB4
antibody, showed no difference between the two genotypes,
regardless of dDox (for developmental Dox, see below) treat-
ment (Figures S6B and S6C). Finally, ErbB4 tyrosine phosphor-
ylation, in response to NRG1 stimulation, in acutely isolated
forebrain slices was similar between the genotypes (Fig-
ure S6B). Together, these results suggest that basal and
NRG1-induced ErbB4 activity is similar between control and
ctoNrg1 mice.
To determine if ErbB4 is involved in glutamatergic hypofunc-
tion in ctoNrg1 mice, we tested if the deficits could be
attenuated by ErbB4 heterozygous mutation, to avoid com-
pounding effect of null mutation on the assembly and function
of GABAergic circuitry (Fazzari et al., 2010; Li et al., 2012; Tan
et al., 2012). Heterozygous mutation does not alter the number
of GABAergic interneurons in cortex and hippocampus (Flames
et al., 2004) and did not alter fEPSP slopes, mEPSC frequency
and amplitude, and PPF of fEPSPs in control mice (Figures
4B–4D), in agreement with previous studies (Fazzari et al.,
2010; Huang et al., 2000; Pitcher et al., 2011). However, it
ameliorated NRG1-induced reduction in eIPSC PPR (Figure 4A),
a phenomenon known to depend on ErbB4 (Woo et al., 2007).
Intriguingly, the maximal fEPSP slope and mEPSC frequency in
ctoNrg1 slices remained depressed after ErbB4+/ mutation
(Figures 4B and 4C). Moreover, ErbB4+/mutation did not atten-
uate the elevated PPF of fEPSPs in ctoNrg1 slices (Figure 4D).
Finally, to circumvent possible compensatory or secondary
effects of ErbB4+/ mutation during development, we acutely
inhibited ErbB4 in ctoNrg1 slices with PD158780, an inhibitor
of ErbB4 (Pitcher et al., 2008; Tan et al., 2012). Glutamatergic
transmission remained deficient in treated slices (Figure S7).Together, these results demonstrate that glutamatergic hypo-
function in ctoNrg1 mice may be independent of ErbB4.
Regulation of Synaptic LIMK1 Signaling by
Overexpressed NRG1
LIMK1 interacts with the intracellular domain of NRG1 (Wang
et al., 1998). It phosphorylates and thus inactivates cofilin, an
actin depolymerization factor that binds to F-actin and severs
the filament (Arber et al., 1998; Yang et al., 1998). F-actin poly-
merization could inhibit glutamate release by preventing vesicle
fusion at the active zone (Cingolani and Goda, 2008). Accord-
ingly, LIMK1 has been implicated in the regulation of glutama-
tergic transmission and plasticity (Meng et al., 2002, 2004).
We wondered if LIMK1 contributes to glutamatergic hypofunc-
tion in ctoNrg1 mice. Both endogenous and transgenic NRG1
are enriched in P2 fraction and synaptosomes (Figure 5A).
NRG1 overexpression had no effect on the overall level of
LIMK1 (Figure 5B), but increased its amount in the P2 fraction
and the synaptosomes (Figure 5C), suggesting that overex-
pressed NRG1 may recruit LIMK1 to synaptosomes. Accord-
ingly, phosphorylated cofilin (p-cofilin) was increased in
ctoNrg1 synaptosomes, compared to controls (Figure 5D).
Notably, the increase in both LIMK1 and p-cofilin in syn-
aptosomes was diminished after aDox treatment (Figure 5E),
which turned off the expression of the Nrg1 transgene
(Figure 5F) and attenuated glutamatergic hypofunction (Figures
3B–3D). These observations suggest that the increase in LIMK1
and p-cofilin in synaptosomes correlates with impaired gluta-
matergic transmission.
To test if LIMK1 is necessary for glutamatergic hypofunction,
hippocampal slices were treatedwith S3-11R, a LIMK1 inhibitory
peptide consisting of cofilin phosphorylation consensus site
(Aizawa et al., 2001) or control peptide, Rev-11R, which contains
the reversed cofilin sequence (Figure 6A). Both peptides have a
stretch of eleven arginines (11R) to facilitate delivery into hippo-
campal neurons (Fukazawa et al., 2003) (Figure 6B). mEPSC
frequency remained lower in ctoNrg1 slices in the presence of
control peptide Rev-11R, compared to controls (Figure 6C). In
contrast, S3-11R ameliorated the reduction inmEPSC frequency
(Figure 6C). It also reduced elevated PPR (Figure 6D) and allevi-
ated I/O depression in ctoNrg1 slices (Figure 6E). These results
indicate that impaired glutamate release in ctoNrg1 slices
requires LIMK1 activity. Together with correlative results
above (Figure 5), these observations provide evidence that
LIMK1 may be necessary for glutamatergic dysfunction due to
NRG1 overexpression, thereby identifying a pathophysiological
mechanism.
Induction of Synaptic and Behavioral Deficits
by Adulthood NRG1 Overexpression
To determine whether NRG1 overexpression in adulthood is
sufficient to cause synaptic dysfunction and behavioral deficits,
ctoNrg1mice were treated with dDox immediately after birth for
8 weeks (Figure 7A). HA-NRG1 expression was suppressed by
dDox completely after P3 and remained undetectable until
11 weeks of age (i.e., three weeks after dDox removal) (Figures
7B and 7C). Control mice were subjected to identical dDox treat-
ment to minimize possible side-effects of dDox.Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc. 649
Figure 4. No Effect of ErbB4 Mutation on Glutamatergic Impairment in ctoNrg1 Mice
(A) ErbB4 heterozygous mutation attenuated NRG1-mediated PPR reduction in both control and ctoNrg1 hippocampal slices. Slices were subjected to a pair of
stimulations in the absence or presence of NRG1. Left, representative eIPSC traces in ctoNrg1 and ctoNrg1;ErbB4+/ slices; right, quantitative data. n = 10 cells
from 3 mice for each group. **p < 0.01, one-way ANOVA.
(B) No effect of ErbB4 heterozygous mutation on maximal fEPSP slope in ctoNrg1 hippocampal slices. Left, representative I/O curves in control, ErbB4+/,
ctoNrg1, and ctoNrg1;ErbB4+/ slices; right, quantitative data. n = 12 slices from 3 mice for each group. **p < 0.01, *p < 0.05, #p > 0.05, one-way ANOVA.
(C) Reduced mEPSC frequency in ctoNrg1 CA1 pyramidal neurons was not altered by ErbB4 heterozygous mutation. Left, representative mEPSC traces in
control, ErbB4+/, ctoNrg1, and ctoNrg1;ErbB4+/ slices; right, quantitative data. n = 10 cells from 3 mice for each group. ***p < 0.001, #p > 0.05, one-way
ANOVA.
(D) ErbB4 heterozygous mutation had no effect on elevated PPF at ctoNrg1 SC-CA1 synapses. Top, representative traces in control, ErbB4+/, ctoNrg1, and
ctoNrg1;ErbB4+/ slices; right, quantitative data at 20 ms interval, n = 12 slices from 3 mice for each group. **p < 0.01, #p > 0.05, one-way ANOVA. Data were
presented as mean ± SEM.
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ctoNrg1 slices, compared to treated controls (Figure 7D), indi-
cating impaired glutamatergic transmission. mEPSC frequency,
but not amplitude, was decreased in slices from dDox-treated
ctoNrg1 mice, compared to dDox-treated controls (Figure 7E).
This reduction was associated with increased PPF, suggesting
lowered release probability (Figure 7F). The glutamatergic defi-
cits were similar to those observed in nontreated ctoNrg1 mice
where NRG1 was higher during development and in adulthood
(Figure 3). These results indicate that NRG1 overexpression in
adulthood alone is sufficient to cause glutamatergic hypofunc-
tion. dDox-treated ctoNrg1mice were hyperactive and impaired
in PPI, spatial learning and memory (Figures 7H–7K), demon-
strating that NRG1 increase in adulthood was able to cause
behavioral deficits. Notably, mIPSC amplitudes in dDox-treated
ctoNrg1 slices were similar to those in dDox-treated controls650 Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc.(Figure 7G), suggesting that GABAergic deficits observed in
ctoNrg1 mice (Figures 3E and S4E) cannot be induced by
NRG1 overexpression in adulthood alone.
DISCUSSION
In this study, we modeled in mice NRG1 overexpression that is
observed in schizophrenic patients. The major findings of our
study are as follows. First, we showed that ctoNrg1 mice
exhibited schizophrenia-related behavioral deficits including
hyperactivity, impaired PPI, reduced social interaction and
cognitive deficits (Figure 2). Intriguingly, after NRG1 returned
to normal levels in adulthood, behavioral deficits were amelio-
rated in ctoNrg1 mice (Figure 2). The reversibility of the deficits
by turning off NRG1 overexpression suggests that the pheno-
types in ctoNrg1 mice were due to the transgene expression,
Figure 5. Synaptic Recruitment and Activation of LIMK1 by Overexpressed NRG1
(A) NRG enrichment in P2 and synaptosomes in ctoNrg1 forebrains. Subcellular fractions were subjected to western blotting with indicated antibodies. Left,
representative blots; right, quantitative data where NRG1 levels were normalized by synaptotagmin (Syt1), and those in controls were taken as 1. n = 3 per
genotype; ***Genotype F (1, 8) = 124.48, p < 0.001, two-way ANOVA. N, nucleus; C, cytoplasm; Syn, synaptosomes.
(B) Similar levels of LIMK1 in control and ctoNrg1 forebrains. Homogenates of individual control (lanes 1–4) and ctoNrg1 (5–8) mice were subjected to western
blotting with antibodies against LIMK1 and a-tubulin. Left, representative blots; right, quantitative data where LIMK1 was normalized by a-tubulin. n = 4 per
genotype; p > 0.05, t test.
(C) Increased LIMK1 in P2 and synaptosomes of ctoNrg1 forebrains. Left, representative blots; right, quantitative data. LIMK1 in cytoplasm was normalized by
tubulin while LIMK1 in P2 and synaptosomes was normalized by Syt1. Levels in control mice were taken as 1. n = 3 per genotype; **Genotype F (1, 12) = 17.73,
p < 0.01, two-way ANOVA.
(D) Increased p-cofilin in P2 and synaptosomes of ctoNrg1mice. Left, representative blots; right, quantitative data where p-cofilin was normalized by total cofilin.
Data from controls were taken as 1. n = 3 per genotype; ***Genotype F (1, 8) = 26.68, p < 0.001, two-way ANOVA.
(E) Similar levels of LIMK1 and p-cofilin in P2 and Syn in aDox-treated control and ctoNrg1 forebrains. Left, representative blots; right, quantitative data where
LIMK1 in cytoplasm was normalized by tubulin and that in P2 and synaptosomes by Syt1, p-cofilin was normalized by total cofilin; and those in controls were
taken as 1; n = 3 per genotype; For LIMK1, Genotype F (1, 8) = 0.26, p > 0.05, two-way ANOVA; for p-cofilin, Genotype F (1, 8) = 0.00, p > 0.05, two-way ANOVA.
(F) HA-NRG1 was not detectable in forebrains of aDox-treated mice. Left, representative blots; right, quantitative data where NRG1 levels were normalized by
Syt1, and those in controls were taken as 1; n = 3 per genotype; Genotype F (1, 8) = 1.57, p > 0.05, two-way ANOVA. Data were presented as mean ± SEM.
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versely, increase of NRG1 levels in adulthood alone was suffi-
cient to cause behavioral deficits (Figure 7). These observations
demonstrate that behavioral deficits in ctoNrg1 mice not only
require continuous NRG1 abnormality, but also can be suffi-
ciently induced in adult mice by abnormal NRG1 expression.
These results suggest that relevant schizophrenia may benefit
from therapeutic intervention to restore NRG1 signaling in
adulthood. Second, our studies indicate that NRG1 overexpres-
sion impairs neurotransmission at glutamatergic as well as
GABAergic synapses. The glutamatergic hypofunction is likelydue to impaired glutamate release whereas GABAergic
dysfunction is caused by reduction of GABAA receptor (Fig-
ure 3). Notably, like behavioral deficits, synaptic dysfunction
also requires continuous NRG1 overexpression in adulthood
(Figure 3) and glutamatergic hypofunction can be sufficiently
induced by adult NRG1 overexpression (Figure 7). These results
underscore synaptic dysfunction as a cellular mechanism for
behavioral deficits. Third, we show that LIMK1 level and activity
in ctoNrg1 synaptosomes correlate with glutamatergic hypo-
function (Figure 5). Importantly, impaired glutamate release
in ctoNrg1 brain slices requires LIMK1 activity (Figure 6),Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc. 651
Figure 6. Inhibition of LIMK1 Ameliorated Glutamatergic Impairment in ctoNrg1 Slices
(A) Amino acid sequences of LIMK1 control (Rev-11R) and inhibitory peptide (S3-11R).
(B) Penetration of FITC-labeled S3-11R into neurons of hippocampal slices. Bar, 20 mm.
(C) Treatment with S3-11R, but not Rev-11R, attenuated mEPSC frequency reduction in ctoNrg1 CA1 pyramidal neurons. Hippocampal slices were treated with
1 mM S3-11R and Rev-11R, respectively. Left, representative traces; right, quantitative data. Rev-11R: n = 8 cells from 3 mice per genotype, S3-11R: n = 8 cells
from 3 control mice, n = 9 cells from 3 ctoNrg1 mice; *p < 0.05, #p > 0.05, one-way ANOVA.
(D) S3-11R, but not Rev-11R, reduced PPF at SC-CA1 synapses in ctoNrg1mice. Slices were treated as in (C). Top, representative traces; bottom, quantitative
data. Rev-11R: n = 9 slices from 3 control mice, n = 10 slices from 3 ctoNrg1mice, S3-11R: n = 8 slices from 3 mice per genotype; **Genotype F (3, 155) = 88.07,
p < 0.01, two-way ANOVA.
(E) Partial recovery of I/O curves at ctoNrg1 SC-CA1 synapses by S3-11R. Top, representative traces; bottom, quantitative data. Rev-11R: n = 9 slices from 3
control mice, n = 10 slices from 3 ctoNrg1mice, S3-11R: n = 8 slices from 3 control mice, n = 9 slices from 3 ctoNrg1mice; **Genotype F (3, 416) = 31.32, p < 0.01,
two-way ANOVA. Data were presented as mean ± SEM.
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Figure 7. Adult NRG1 Overexpression Is Sufficient to Cause Glutamatergic Impairment and Behavioral Deficits
(A) Diagram of dDox treatment and tests. Mice were fed with Dox-containing drinking water fromP0 till 8 weeks of age, when Dox was omitted. Three weeks later,
mice were subjected to analysis. Such treatment was designated as dDox for Dox treatment during development.
(B) Expression of the HA-NRG1 transgene in forebrains was not detectable after P3 in mice being treated by dDox.
(C) HA-NRG1 was not detectable in forebrains of dDox-treated mice at 8 weeks of age, but was detectable at 11 weeks of age (i.e., 3 weeks after dDox with-
drawal).
(D) Depressed I/O curves in dDox-treated ctoNrg1mice compared to dDox-treated controls. Top, representative traces; bottom, quantitative data; n = 12 slices
from 4 dDox-treated control mice, n = 11 slices from 5 dDox-treated ctoNrg1mice; **Genotype F (1, 273) = 40.77, p < 0.01, two-way ANOVA. Blank and yellow
histograms/curves represent data from dDox-treated control and ctoNrg1 mice, respectively.
(E) Decreased mEPSC frequency, but not amplitude, in CA1 pyramidal neurons of dDox-treated ctoNrg1mice compared to controls. Top, representative traces;
bottom, quantitative data; n = 9 cells from 3 dDox-treated control mice; and n = 10 cells from 4 dDox-treated ctoNrg1 mice; **p < 0.01, t test.
(F) Elevated PPF at SC-CA1 synapses in dDox-treated ctoNrg1mice compared to controls. Left, representative traces; right, quantitative data; n = 10 slices from
4 dDox-treated control mice; n = 10 slices from 5 dDox-treated ctoNrg1 mice; **Genotype F (1, 90) = 70.21, p < 0.01, two-way ANOVA.
(G) Normal mIPSC in dDox-treated ctoNrg1 mice compared to controls. Left, representative traces; right, quantitative data; n = 10 cells from 4 dDox-treated
control mice; n = 12 cells from 4 dDox-treated ctoNrg1 mice; p > 0.05, t test.
(H) Increased travel distance by dDox-treated ctoNrg1 mice in open field test for 30 min compared to controls. n = 10 per genotype; *p < 0.05, t test.
(I) Reduced PPI in dDox-treated ctoNrg1 mice compared to controls. n = 10 per genotype; *Genotype F (1, 51) = 16.06, p < 0.05, two-way ANOVA.
(J) Increased latency of dDox-treated ctoNrg1mice to reach the hidden platform inMWMcompared to controls. n = 10 per genotype; *Genotype F (1, 68) = 13, p <
0.05, two-way ANOVA.
(K) Reduced platform crossing by dDox-treated ctoNrg1 mice in MWM probe test compared to controls. n = 10 per genotype; *p < 0.05, t test. Data were
presented as mean ± SEM.
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target for intervention.
Both glutamatergic and GABAergic hypofunction have been
implicated in schizophrenia (Lewis and Moghaddam, 2006).
NRG1 and ErbB4 appear to be critical for development and
maturation of GABAergic circuitry (Abe et al., 2011; Cahill
et al., 2012; Fazzari et al., 2010; Flames et al., 2004; Ting et al.,
2011). Acutely, NRG1 promotes GABA release by activating
ErbB4 in GABAergic neurons (Woo et al., 2007) and thus regu-
lates the firing of excitatory neurons and LTP (Chen et al.,2010; Li et al., 2012; Tan et al., 2012; Wen et al., 2010). However,
in ctoNrg1 mice, GABA release was not altered and glutama-
tergic dysfunction does not appear to require ErbB4. First,
ErbB4 level and activity is not altered in ctoNrg1mice (Figure S6).
However, ErbB4 can be activated by acute treatment with exog-
enous NRG1 (Figure S6B). Second, pharmacological inhibition
or geneticmutation of ErbB4, which attenuated NRG1 promotion
of GABA release (Figure 4A), had little effect on glutamatergic hy-
pofunction in ctoNrg1 mice (Figures 4B–4D and S7). These ob-
servations suggest that NRG1 overexpression may causeNeuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc. 653
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ErbB4 activation.
The intracellular domain of NRG1 interacts with LIMK1 (Wang
et al., 1998), a threonine/serine protein kinase implicated in actin
cytoskeletal reorganization. The kinase is localized in both
presynaptic terminals and postsynaptic densities (Wang et al.,
2000; Yildirim et al., 2008) and has been implicated in the regu-
lation of glutamatergic transmission (Meng et al., 2004; Meng
et al., 2002). Intriguingly, LIMK1 and p-cofilin were increased in
synaptosomes of ctoNrg1mice (Figures 5C and 5D) and reduced
upon aDox treatment (Figure 5E). LIMK1-cofilin signaling causes
F-actin polymerization (Arber et al., 1998; Yang et al., 1998)
which has been shown to inhibit glutamate release by preventing
vesicle fusion at the active zone (Cingolani and Goda, 2008; Mo-
rales et al., 2000). Accordingly, some synaptic deficits in ctoNrg1
mice can be attributed to impaired glutamate release: impaired
I/O curve, reduced mEPSC frequency, elevated PPF and slowed
synaptic fatigue (Figures 3B–3D, S4C, and S4D), and these
phenotypes were attenuated upon NRG1 reduction in aDox-
treated ctoNrg1 mice (Figures 3B–3D). Remarkably, acute
inhibition of LIMK1 attenuated glutamatergic hypofunction in
ctoNrg1 slices, suggesting that LIMK1 activity is necessary (Fig-
ure 6). These observations suggest that overexpressed NRG1
may recruit LIMK1 to synapses to alter glutamate release. These
observations identify a cell-autonomous mechanism for NRG1
overexpression to cause synaptic dysfunction.
mRNA levels of GABAAR a1 subunit in the dorsolateral pre-
frontal cortex (DLPFC) were found to be higher in schizophrenic
patients than in control subjects (Impagnatiello et al., 1998; Oh-
numa et al., 1999). Recent studies suggested a reduction in
mRNA levels of GABAAR a1 subunit in the DLPFC of subjects
with schizophrenia (Beneyto et al., 2011; Glausier and Lewis,
2011; Hashimoto et al., 2008). Reasons for this discrepancy
are unknown, but have been attributed to differences in subject
and control population (age and sex) or postmortem intervals
(Glausier and Lewis, 2011). Nevertheless, we found that
GABAAR a1 subunit and mIPSC amplitude were reduced in
ctoNrg1 mice (Figures 3E, 3F and S5A). Since mature type I
NRG1 is diffusible, the reduction of GABAAR a1 subunit in
ctoNrg1 mice might be through activation of ErbB2 or other
potential coreceptors in pyramidal neurons. This hypothesis
was supported by a previous study that long-term treatment of
hippocampal slices with NRG1 reduced GABAAR a1 subunit
levels (Okada and Corfas, 2004). Alternatively, the reduction
could be due to a homeostatic mechanism in pyramidal neurons,
which might decrease inhibition response to compensate for
glutamatergic hypofunction (Figures 3B–3D and S4D). The
reduction of mIPSC amplitudes in ctoNrg1mice was diminished
after aDox treatment (Figure 3E) and notably, mIPSC amplitudes
were similar between dDox-treated control and ctoNrg1 mice
(Figure 7G). These results suggest that adult overexpression of
NRG1 is required to maintain, but not sufficient to cause the
reduction in mIPSC amplitudes.
Our work corroborates recent findings that transgenic mice
expressing NRG1 under the control of Thy-1 and EF-1a pro-
moters exhibit similar, but not identical, behavioral deficits
(Deakin et al., 2009, 2012; Kato et al., 2010). For example, tremor
and impaired motor skill were observed in Thy1-Nrg1 transgenic654 Neuron 78, 644–657, May 22, 2013 ª2013 Elsevier Inc.mice (Deakin et al., 2009) but not in ctoNrg1 mice (Figure S1A).
EF-1a-Nrg1 mice, where NRG1 was expressed in all cells in
the body, albeit hyperactive, were normal in PPI test (Kato
et al., 2010). The differences in these two strains and between
them and ctoNrg1 mice may be due to variation in expression
patterns and levels ofNrg1 transgene (for example hundred folds
above normal in Thy-1-Nrg1 mice) (Deakin et al., 2009). Never-
theless, these observations revealed pathogenic effects of
NRG1 overexpression in mice during development. Our study
further demonstrates that these pathogenic effects can be
repaired in adult mice and raises the possibility that relevant
schizophrenia may benefit from therapeutic approaches to
restore NRG1 signaling.
EXPERIMENTAL PROCEDURES
Generation of ctoNrg1Mice
NRG1Ib1a (kindly provided by Dr. Douglas Falls, Emory University) was cloned
into the EcoRV site of pMM400 (kindly provided by Dr. Joe Tsien, Georgia
Regents University). An HA tag was inserted between Ig and EGF domains.
A NotI fragment containing the transgene was used for transgenic mouse
production. C57BL/6-CBA(J) F2 founders (i.e., TRE-Nrg1) were identified by
PCR with primers (forward atctggtcagaaaagacaat, in pMM400; reverse
tgagtgaggagtactcgg in NRG1Ib1a). TRE-Nrg1 mice were backcrossed with
C57BL/6N mice for 6 generations before crossing with CamK2a-tTA mice
(Jackson Lab, stock number 007004). Animals were housed in rooms at
23C in a 12 hr light/dark cycle and with food and water available ad libitum.
In some experiments, Dox (Sigma-Aldrich, catalog number D9891) was added
to drinking water at 1 mg/ml in 2.5% sucrose. All animal experimental proce-
dures were approved by the Institutional Animal Care and Use Committee of
Georgia Regents University.
Immunohistochemical and Stereological Analysis
Anesthetized mice were perfused transcardially with 4% paraformaldehyde
(PFA) in PBS and tissues were fixed in 4% PFA at 4C for 5 hr. Frozen brain
blocks were cut into 40-mm-thick sections on a vibrating microtome
(VT1000S; Leica Microsystem). Sections were permeabilized with 0.3%
Triton X-100 and 5% BSA in PBS and incubated with primary antibodies
at 4C overnight. After washing with PBS for 3 times, samples were incu-
bated with Alexa Fluor-conjugated secondary antibodies (1:1,000, Invitrogen)
for 1 hr at room temperature. Samples were mounted with Vectashield
mounting medium (Vector) and images were taken by Zeiss LSM510
confocal microscope. Primary antibodies were prepared in PBS containing
0.3% Triton X-100 by the following dilutions: mouse anti-NeuN (1:1000,
Millipore), rabbit anti-PV (1:1000, Swant), mouse anti-HA (1:200, Covance).
For stereological analysis, brain blocks were cut transversely into 50-mm-
thick serial sections. Slices for entire dorsal hippocampus were collected.
Every third section, total 8, was subjected to immunofluorescent staining
of NeuN and PV. Unbiased stereological analysis of total neurons, PV-
positive GABAergic interneurons was carried out with the optical fractionator
technique by using StereoInvestigator software, as previously described
(Stranahan et al., 2012).
Behavior Analysis
To eliminate possible effects that may be associated with the insertion of
transgenes, TRE-Nrg1 and Camk2a-tTA mice were used as controls in behav-
ioral analysis as described previously (Kellendonk et al., 2006). Behavioral
tests were performed in three4-month-old male mice, except social interac-
tion where females were used. The investigators for behavioral tests were blind
to genotypes and/or Dox administration. Both control and ctoNrg1mice were
treated with Dox to avoid possible compounding effects of Dox on behaviors
(Kellendonk et al., 2006; Mayford et al., 1996). Mice were not tested on the
same behavioral paradigms more than once, to avoid effects of learning and
memory (Kellendonk et al., 2006).
Neuron
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Two-way ANOVA was used in behavioral analysis including PPI, rotarod,
8-ARM, social interaction, training in MWM, and effects of clozapine and
electrophysiological studies including I/O curve, PPR, and synaptic fatigue.
One-way ANOVAwas used for analysis of data from three ormore groups. Stu-
dent’s t test was used to compare data from two groups. Data were expressed
as mean ± SEM unless otherwise indicated.
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